Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA OFFICE OF EPIDEMIOLOGY DIRECTOR FAICH MOVING TO BESSELAAR-PACT

Executive Summary

FDA OFFICE OF EPIDEMIOLOGY DIRECTOR FAICH MOVING TO BESSELAAR-PACT as a VP in August. The 47 year-old Faich, MD, who will retire from the agency after 20 years in the Public Health Service, has served as director of the Office of Epidemiology and Biostatistics for six years, where he has coordinated adverse reaction reporting and post-marketing surveillance. FDA has not named a replacement for the position. The agency reportedly has not yet decided whether it will conduct an internal or external search for his successor. Next in line to Faich is the office's deputy director Charles Anello, who has been with agency for 20 years. Prior to coming to FDA, Faich spent two years in the Surgeon General's Office. Before that he performed epidemiological research for the Centers for Disease Control for 12 years. At Besselaar, Faich will be responsible for Phase IV studies and drug safety reviews. Corning Laboratory Science Division subsidiary Besselaar, founded by former Merck exec G.H. Besselaar, acquired PACT (Philadelphia Association for Clinical Trials) in December ("The Pink Sheet" Jan. 1, T&G-10). The new corporation says it conducts Phase I-IV studies for at least half of the top 50 U.S. pharmaceutical manufacturers. The company also maintains offices in Europe, Japan and Australia.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017374

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel